Evolution of the Average Target: AbbVie Inc.

Evolution of the Target Price: AbbVie Inc.

Changes in Analyst Recommendations: AbbVie Inc.

8fabf9c1d692c9b8f5.MTbhikNsp9kHYK1KMgVZ0ABHYAjkcGIOUW7rwfwP8KQ.HG6r0HUhzqhFBtkrVVIblVpqNku3RQdWMzS49IZWnP13QY_rIgnFtWIrnQ~68b615f978b163d25178051632649b66
Citigroup Adjusts Price Target on AbbVie to $210 From $215, Keeps Buy Rating Apr. 11 MT
Morgan Stanley Adjusts Price Target on AbbVie to $241 From $239, Keeps Overweight Rating Apr. 09 MT
Berenberg Adjusts Price Target on AbbVie to $195 From $165, Maintains Hold Rating Mar. 12 MT
Redburn Atlantic Adjusts Price Target on AbbVie to $234 From $216 Mar. 10 MT
Wells Fargo Adjusts Price Target on AbbVie to $240 From $210, Keeps Overweight Rating Mar. 05 MT
TD Cowen Adjusts Price Target on AbbVie to $250 From $225, Maintains Buy Rating Mar. 04 MT
HSBC Adjusts AbbVie Price Target to $230 From $220, Maintains Buy Rating Feb. 27 MT
Daiwa Securities Adjusts Price Target on AbbVie to $190 From $180, Keeps Neutral Rating Feb. 04 MT
UBS Adjusts Price Target on AbbVie to $190 From $181, Maintains Neutral Rating Feb. 03 MT
Truist Securities Adjusts AbbVie Price Target to $217 From $211, Maintains Buy Rating Feb. 03 MT
Deutsche Bank Adjusts AbbVie Price Target to $173 From $177, Maintains Hold Rating Feb. 03 MT
Leerink Adjusts Price Target on AbbVie to $210 From $206, Maintains Outperform Rating Feb. 03 MT
Goldman Sachs Adjusts Price Target on AbbVie to $212 From $208, Keeps Buy Rating Feb. 03 MT
Guggenheim Adjusts Price Target on AbbVie to $214 From $212, Keeps Buy Rating Feb. 03 MT
Raymond James Adjusts Price Target on AbbVie to $220 From $218, Keeps Outperform Rating Feb. 03 MT
Wolfe Research Adjusts Price Target on AbbVie to $220 From $205, Keeps Outperform Rating Feb. 03 MT
Wells Fargo Adjusts Price Target on AbbVie to $210 From $195, Keeps Overweight Rating Feb. 03 MT
Citigroup Adjusts Price Target on AbbVie to $205 From $215, Maintains Buy Rating Jan. 28 MT
Piper Sandler Adjusts Price Target on AbbVie to $227 From $220, Keeps Overweight Rating Jan. 27 MT
Goldman Sachs Adjusts Price Target on AbbVie to $208 From $205, Keeps Buy Rating Jan. 27 MT
Guggenheim Adjusts Price Target on AbbVie to $212 From $221, Maintains Buy Rating Jan. 17 MT
Redburn Atlantic Adjusts Price Target on AbbVie to $216 From $214, Maintains Buy Rating Jan. 17 MT
Redburn Atlantic Adjusts Price Target on AbbVie to $214 From $216, Keeps Buy Rating Jan. 10 MT
Truist Trims Price Target on AbbVie to $211 From $215, Keeps Buy Rating Jan. 08 MT
Piper Sandler Adjusts AbbVie Price Target to $220 From $212, Maintains Overweight Rating Dec. 17 MT
More recommendations

Consensus 4m Revision of opinion Divergence of analysts' opinions Divergence of Target Price Ecart obj. / dr
+16.43%
+17.32%
+9.63%
+77.23%
+19%
+29.86%
+6.35%
+35.73%
+12.43%
+7.02%
Average +23.10%
Weighted average by Cap. +22.78%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
180.37USD
Average target price
210.01USD
Spread / Average Target
+16.43%
High Price Target
250.00USD
Spread / Highest target
+38.60%
Low Price Target
173.00USD
Spread / Lowest Target
-4.09%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Citigroup
Morgan Stanley
Berenberg Bank
Redburn Atlantic
Wells Fargo Securities
TD Cowen
HSBC
Daiwa Securities
UBS
Truist Securities
Deutsche Bank Securities
Leerink Partners
Goldman Sachs
Guggenheim
Raymond James
Wolfe Research
Piper Sandler
JPMorgan Chase
BMO Capital
Argus
Cantor Fitzgerald
Evercore ISI
Barclays
Mizuho Securities
Morningstar
William Blair & Co.
BofA Securities
Atlantic Equities
SVB Securities LLC
Credit Suisse
Societe Generale
Cowen
Redburn
SVB Leerink
RBC Capital Markets
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings

Quarterly revenue - Rate of surprise